HHSN261201400051C;TOPIC 309 DEVELOPMENT OF LOW COST, SMALL SAMPLE MULTI-ANALYTE TECHNOLOGIES FOR CANCER DIAGNOSIS, PROGNOSIS AND EARLY DETECTION;TITLE: FLOWNOSTICS: PORTABLE MULTIPLEX ANALYSIS SYSTEM;

HHSN261201400051C；主题 309 开发用于癌症诊断、预后和早期检测的低成本、小样本多分析物技术；标题：Flownostics：便携式多重分析系统；

• 批准号: 8942670
• 负责人: SUNG HWAN CHO
• 金额: $ 97.64万
• 依托单位: NANOCELLECT BIOMEDICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-16 至 2016-09-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8942670
• 关键词: Address; Biological Assay; Biological Markers; Blood specimen; Cell Separation; Clinical; Code; Color; Complex; Detection; Development; Devices; Disease; Early Diagnosis; Hematopoietic Neoplasms; Improve Access; Lasers; Malignant Neoplasms; Microfluidic Microchips; Microscopic; Mission; Monitor; Optics; Proteins; Public Health; Reporting; Sampling; Screening for cancer; Staging; Systems Analysis; Technology; United States National Institutes of Health; Urine; Validation; base; cancer diagnosis; commercialization; cost; design; detector; high throughput analysis; improved; micro-total analysis system; novel; outcome forecast; point-of-care diagnostics; software systems

Cancer is a complex and diverse disease whose treatment can be improved by more sophisticated early detection and monitoring. NanoCeliect Biomedical, Inc. proposes to build a lab-on-a-chip microfluidic device platform that can detect and quantify at least 32 multiplexed analytes for the detection and monitoring of cancer from blood or urine samples. This novel "FlowNostics" device will utilize 32 kinds of microscopic beads, coded by their size and color, that will be detected by a combination of impedence and a single optical detector to detect emission from single 405 nm laser excitation. NanoCellect's FlowNostics platform will reduce the expense and complexity of flow cytometric-based multiplex assays to increase access and enable point-of-care diagnostics. NanoCellect's FlowNostics technology will improve public health and help to fulfill the mission of the NIH and NCI by improving access to sophisticated analytics at a fraction of the cost and complexity of current devices. NanoCellect's aim is to enable reporting of the presence of cancer from routine blood samples taken during check-ups, which will aid in the early detection of cancer and allow treatments before cancers have reached an advanced stage.

癌症是一种复杂而多样的疾病，可以通过更复杂的早期改善治疗 检测和监测。 Nanoceliect Biomedical，Inc。提议建立一个芯片上的实验室微流体设备 可以检测和量化至少32个多路复用分析物以检测和监视的平台 血液或尿液样本中的癌症。这款小说的“ Flownostics”设备将利用32种微观珠， 根据其大小和颜色编码，这将通过障碍和单个光学检测器的组合来检测 检测单个405 nm激光激发的发射。 Nanocelect的FlownoStics平台将减少 基于流式细胞米的多重测定的费用和复杂性，以增加访问并启用护理点 诊断。 Nanocelect的FlownoStics技术将改善公共卫生，并帮助实现NIH的使命和 NCI通过以当前设备的成本和复杂性的一小部分来改善对复杂分析的访问。 纳米细胞的目的是能够报告从常规血样中报告的癌症 检查，这将有助于早期发现癌症，并允许癌症达到癌症的治疗 高级舞台。